CClinicalTrials.gg
CompletedNCT07761832Updated Aug 12, 2026

Hemoglobin Trends as a Predictor of Outcomes in Critically Ill Patients (The TRENT-ICU Study)

An observational study in Critical Illness and Anemia, sponsored by Hospital H+ Queretaro. Completed at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Hospital H+ Queretaro · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
128
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate if early absolute hemoglobin decline (during the first 24 hours of admission) can predict prolonged intensive care unit stay (8 days or more) and in-hospital mortality in critically ill adult patients.

The main questions it aims to answer are:

Does absolute hemoglobin decline during the first 24 hours of admission independently predict prolonged intensive care unit stay in critically ill adult patients?

Does absolute hemoglobin decline during the first 24 hours of admission independently predict in-hospital mortality in critically ill adult patients?

Participants will:

Have their routine clinical and laboratory data reviewed retrospectively from their electronic health records (including baseline hemoglobin and a second hemoglobin determination approximately 24 hours after admission). No additional interventions or extra blood draws will be performed beyond routine clinical care.

02

Conditions studied

  • Critical Illness
  • Anemia

Keywords

  • critical care
  • Hemoglobins
  • Blood Transfusion
  • Prognosis
  • Intensive Care Units
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

dult patients admitted to the Intensive Care Unit at Hospital H+ Querétaro, Mexico, between January 2024 and January 2026, who required an ICU stay of more than 48 hours and had serial hemoglobin measurements during routine medical care.

Inclusion criteria

  • Adult patients (aged 18 years or older) admitted to the Intensive Care Unit (ICU) between January 2024 and January 2026.
  • ICU length of stay greater than 48 hours.
  • At least two hemoglobin determinations obtained with an interval of approximately 24 hours apart during routine medical care.

Exclusion criteria

Exclusion Criteria:

  • Massive bleeding upon ICU admission.
  • Massive transfusion protocol activation.
  • Pregnancy.
  • Hemoglobinopathies.
  • Active hemolytic anemia.
  • Medical records with insufficient information for analysis.
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
128 participants (actual)
Patient registry
No

Groups and cohorts

  • Critically Ill Adult Patients

    Adult patients admitted to the intensive care unit with an ICU stay of more than 48 hours and at least two hemoglobin determinations obtained approximately 24 hours apart during routine care.

    Other: Early Absolute Hemoglobin Decline

Interventions

  • OtherEarly Absolute Hemoglobin Decline

    Measurement of the absolute difference in hemoglobin concentration (g/dL) between baseline ICU admission and approximately 24 hours post-admission. Data was collected retrospectively from electronic health records.

05

What researchers measure

Primary outcomes

  1. Prolonged Intensive Care Unit Stay

    Incidence of prolonged intensive care unit (ICU) length of stay, defined a priori as an ICU stay equal to or greater than 8 days.

    Time frame: From ICU admission up to 28 days

Secondary outcomes

  1. In-Hospital Mortality

    Incidence of all-cause mortality recorded at hospital discharge.

    Time frame: From ICU admission up to 30 days

06

Study locations

1 site
  • Hospital H+ Querétaro, Santiago de Querétaro, Querétaro
    Querétaro City, Querétaro 76000, Mexico
07

Registry details

Key details

Study ID
NCT07761832
Lead sponsor
Hospital H+ Queretaro
Responsible party
Jose J Zaragoza, MD MSc (Principal Investigator, Hospital H+ Queretaro) — Principal investigator
First posted
Aug 12, 2026
Start date
Jul 31, 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Aug 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion